Cargando…

CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors

Depleting regulatory T cells (T(reg) cells) to counteract immunosuppressive features of the tumor microenvironment (TME) is an attractive strategy for cancer treatment; however, autoimmunity due to systemic impairment of their suppressive function limits its therapeutic potential. Elucidating approa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haiping, Franco, Fabien, Tsui, Yao-Chen, Xie, Xin, Trefny, Marcel P., Zappasodi, Roberta, Mohmood, Syed Raza, Fernández-García, Juan, Tsai, Chin-Hsien, Schulze, Isabell, Picard, Florence, Meylan, Etienne, Silverstein, Roy, Goldberg, Ira, Fendt, Sarah-Maria, Wolchok, Jedd D., Merghoub, Taha, Jandus, Camilla, Zippelius, Alfred, Ho, Ping-Chih
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7043937/ https://www.ncbi.nlm.nih.gov/pubmed/32066953 http://dx.doi.org/10.1038/s41590-019-0589-5

Ejemplares similares

Immunotherapy and the belly of the beast
por: Merghoub, Taha, et al.
Publicado: (2014)

Impairment of Treg suppression by GITR ligation is effective selectively in the context of a pro-inflammatory tumor microenvironment
por: Zappasodi, Roberta, et al.
Publicado: (2014)

Direct comparisons of T cell costimulation and checkpoint blockade in the setting of tumor-targeted monoclonal antibody therapy
por: Khalil, Danny, et al.
Publicado: (2015)

Myeloid-derived suppressor cells and the efficacy of CD8(+) T-cell immunotherapy
por: Lesokhin, Alexander M., et al.
Publicado: (2013)

Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2013)

Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment
por: Budhu, Sadna, et al.
Publicado: (2014)

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors
por: Holmgaard, Rikke B., et al.
Publicado: (2016)

Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model
por: Holmgaard, Rikke B, et al.
Publicado: (2014)

Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism
por: He, Changhao, et al.
Publicado: (2022)

Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection
por: Zamarin, Dmitriy, et al.
Publicado: (2013)

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy
por: Ricca, Jacob M., et al.
Publicado: (2018)

Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia
por: Wang, Weiyi, et al.
Publicado: (2021)

An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
por: Maus, Marcela V, et al.
Publicado: (2017)

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
por: Zamarin, Dmitriy, et al.
Publicado: (2017)

Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma
por: Budhu, Sadna, et al.
Publicado: (2021)

Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
por: Avogadri, Francesca, et al.
Publicado: (2010)

APR-246 increases tumor antigenicity independent of p53
por: Michels, Judith, et al.
Publicado: (2023)

Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
por: Davar, Diwakar, et al.
Publicado: (2022)

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2009)

Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus
por: Oseledchyk, Anton, et al.
Publicado: (2018)

T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks
por: Tkach, Karen E, et al.
Publicado: (2014)

Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine
por: Campesato, Luis Felipe, et al.
Publicado: (2020)

Refusing to TAP out: 16 new human TEIPPs identified
por: Gigoux, Mathieu, et al.
Publicado: (2018)

Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope
por: Schaer, David A., et al.
Publicado: (2011)

Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
por: Gupta, Aditi, et al.
Publicado: (2021)

Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
por: Srinivasan, Roopa, et al.
Publicado: (2004)

Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer
por: Zamarin, Dmitriy, et al.
Publicado: (2014)

Phase Ib Trial of Phenformin in Patients with V600-mutated Melanoma Receiving Dabrafenib and Trametinib
por: Chapman, Paul B., et al.
Publicado: (2023)

Self-antigen–specific CD8(+) T cell precursor frequency determines the quality of the antitumor immune response
por: Rizzuto, Gabrielle A., et al.
Publicado: (2009)

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype
por: Hirschhorn-Cymerman, Daniel, et al.
Publicado: (2012)

Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIC melanoma characterized by a BRAFV600E/K mutation
por: Momtaz, Parisa, et al.
Publicado: (2017)

Shared cancer neoantigens: Making private matters public
por: Klebanoff, Christopher A., et al.
Publicado: (2018)

The many faces of the anti-COVID immune response
por: Vardhana, Santosha A., et al.
Publicado: (2020)

Chromatin states define tumor-specific T cell dysfunction and reprogramming
por: Philip, Mary, et al.
Publicado: (2017)

Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
por: Cohen, Adam D., et al.
Publicado: (2010)

Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
por: Kraehenbuehl, Lukas, et al.
Publicado: (2022)

Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
por: Choi, Hyejin, et al.
Publicado: (2019)

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness
por: Hirschhorn, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kesh26sg3q8s5h5uacu0clvu3h